MedPath

An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment

Completed
Conditions
Breast Cancer
Registration Number
NCT00737009
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
259
Inclusion Criteria
  • Postmenopausal woman with early breast cancer who are prescribed with anastrozole as adjuvant endocrine therapy under the routine clinical practice.
  • Histologically or cytologically proven to be HR+(ER or PR +)
  • No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
  • Provision of written informed consent
Read More
Exclusion Criteria
  • Recurrence of breast cancer
  • Known hypersensitivity to anastrozole or to any of its excipients
  • Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize adherence with the trial protocol: Amenorrhea<12 months and a intact uterus; Previous inclusion in the present study; Participation in a other clinical study during the last 30 days·
  • Women who does not agreed to participate the program
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes)every 3- 6 months (4 visit in one year)
Secondary Outcome Measures
NameTimeMethod
Describe menopausal symptomsevery 3- 6 months (4 visit in one year)
Estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-upevery 3- 6 months (4 visit in one year)
Identify predictors of non- adherenceevery 3- 6 months (4 visit in one year)
The proportion of DFS after 1 year follow-upevery 3- 6 months (4 visit in one year)

Trial Locations

Locations (1)

Research Site

🇻🇳

Hue, Vietnam

© Copyright 2025. All Rights Reserved by MedPath